What is Tezspire (tezepelumab-ekko) for?

Tezspire (tezepelumab-ekko) is a medication indicated as an add-on maintenance therapy for severe asthma in adults and pediatric patients aged 12 years and older. It can prevent severe asthma attacks and improve breathing by blocking thymic stromal lymphopoietin (TSLP) and reducing the inflammation of the airways.

How does Tezspire (tezepelumab-ekko) work?

Tezspire (tezepelumab-ekko) contains tezepelumab, which is an antibody that binds to thymic stromal lymphopoietin (TSLP), a protein that is involved in the development of asthma. By blocking the action of TSLP, it can reduce the inflammation of the airways and prevent severe asthma attacks.

How is Tezspire (tezepelumab-ekko) taken?

The recommended dosage for Tezspire (tezepelumab-ekko) is an injection of 210 mg under the skin, given once every 4 weeks. If a dose is missed, it should be taken as soon as possible, and subsequent doses should be administered on the usual day. If the next dose is already due, it should be administered as planned. Additional details on dosage and administration can be found in the official prescribing information listed in our references section. It is important to consult with your doctor for personalized dosing instructions.

Are there any known side effects of Tezspire (tezepelumab-ekko)?

Yes, there are potential side effects associated with Tezspire (tezepelumab-ekko). The most common side effects reported during clinical trials include injection site reactions (such as itching, pain, or swelling), headaches, and upper respiratory tract infections. Other less common side effects that have been reported include allergic reactions, hypersensitivity reactions, and anaphylaxis.

It is important to note that not all patients will experience these side effects, and some may experience no side effects at all. If you are experiencing any concerning symptoms after starting treatment with Tezspire, you should talk to your doctor or healthcare provider as soon as possible. They can provide guidance on the best course of action and help you manage any side effects that you may be experiencing.

Clinical trials

Tezspire (tezepelumab-ekko) received FDA approval as an add-on maintenance treatment for individuals aged 12 years and older with severe asthma, based on data from the PATHFINDER clinical trial program. The program included the pivotal NAVIGATOR Phase III trial (NCT03347279), which involved randomly assigning adult and pediatric patients with severe, uncontrolled asthma who were receiving standard of care to receive Tezspire or placebo subcutaneously every four weeks for 52 weeks in a double-blinded, placebo-controlled trial.

NAVIGATOR’s primary efficacy outcome was the annualized rate of asthma exacerbations over 52 weeks. Secondary outcomes included Tezspire’s impact on lung function, asthma control, and health-related quality of life. Compared to placebo, patients receiving Tezspire exhibited a significant reduction in the annualized rate of asthma exacerbations, as well as improved lung function, asthma control, and quality of life.

Further information regarding the safety and effectiveness of Tezspire for its approved indication can be found in the summary of product characteristics in the resources section.